Authoring CMC Module 3 and Module 2.3 (QOS) for Drug Substances
What It Is: The Chemistry, Manufacturing and Controls (CMC) section of a regulatory dossier — specifically Module 3 and the accompanying Module 2.3 Quality Overall Summary (QOS) — forms the scientific backbone of any new drug application. For Drug Substances, this documentation must comprehensively describe the active pharmaceutical ingredient (API): its characterization, manufacturing process, specifications, analytical methods, stability data, and controls.
At ReguLinx, we provide expert authoring and review of Drug Substance CMC sections for regulatory submissions to the US FDA, EMA, PMDA, and other major health authorities. Our consultants have direct, hands-on experience preparing high-quality CTD-format dossiers for commercial products, development-stage APIs, and complex molecules including biologics and large molecules.
Who It Is For: This service is ideal for API manufacturers, pharmaceutical development companies, contract manufacturing organizations (CMOs), and any company requiring robust CMC documentation for regulatory submission or agency review.
Key Benefits:
- Submissions prepared in full compliance with ICH M4Q guidelines and regional regulatory requirements
- Experienced writers who understand health authority expectations and current regulatory standards
- Reduced risk of deficiencies, information requests, and approval delays
- Support for both initial submissions and updates to existing documentation
- Scalable support — from single modules to full dossier authoring
Drug Master File (DMF) — US FDA
What It Is: A Drug Master File (DMF) is a confidential submission to the US FDA that provides detailed information about facilities, processes, and articles used in the manufacture, processing, packaging, and storage of a drug substance. Pharmaceutical companies reference a supplier’s DMF in their own NDA or ANDA without disclosing proprietary information.
ReguLinx provides expert DMF authoring, review, and amendment support to ensure your DMF is well-structured, complete, and fully compliant with FDA requirements. We also manage annual reports and responses to FDA questions regarding your DMF.
Key Benefits:
- Accurate, complete DMF preparation aligned with FDA guidance
- Expert gap analysis of existing DMFs against current expectations
- Support for Type II (Drug Substance) DMFs and related amendments
- Timely responses to FDA queries to protect DMF status and referencing activity
CEP — Certificate of Suitability (European Pharmacopoeia)
What It Is: A Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) demonstrates that an API’s quality is controlled by the relevant Ph. Eur. monograph. Issued by the EDQM, a CEP simplifies the Marketing Authorization Application process across European markets by replacing the need for a full Module 3 Drug Substance section in each submission.
ReguLinx assists API manufacturers with CEP applications — from initial dossier preparation through to revisions and renewals — ensuring accuracy, completeness, and compliance with EDQM requirements.
Key Benefits:
- Simplifies MAA submissions across all Council of Europe member states
- Expert authoring aligned with EDQM application guidelines
- Support for initial CEP, revisions, and renewals
- Reduction of duplication across multiple European submissions
Japan Drug Master File (JDMF)
What It Is: The Japan Drug Master File (MF) is a confidential registration system managed by PMDA, equivalent to the US FDA DMF, used to protect proprietary manufacturing information while allowing marketing authorization applicants to reference the MF in their submissions.
Our team has direct experience with PMDA requirements and can prepare, register, and maintain Japan MF submissions to support your clients’ JNDA or other Japan marketing authorization applications.
AFM/FMA — Accreditation of Foreign Manufacturer (Japan)
What It Is: For pharmaceutical products manufactured outside of Japan to be imported and sold in Japan, the foreign manufacturing facility must obtain Accreditation of Foreign Manufacturer (AFM), known as FMA, from the PMDA. This is a mandatory requirement for all foreign drug manufacturers supplying the Japanese market.
ReguLinx provides full support for AFM/FMA applications, including documentation preparation, translation coordination, and responses to PMDA queries — helping overseas manufacturers enter the Japanese pharmaceutical market with confidence.
CMC Gap Analysis — Drug Substance
What It Is: A CMC gap analysis is a systematic, expert review of your existing Drug Substance regulatory documentation against the current expectations of your target health authority (FDA, EMA, PMDA, etc.). The goal is to identify any gaps, deficiencies, or outdated content before you submit — avoiding costly and time-consuming information requests from regulators.
ReguLinx conducts thorough gap analyses against ICH guidelines and regional requirements, delivering a clear gap report with actionable recommendations to bring your documentation to submission readiness.
Response to Health Authority Questions — Drug Substance
What It Is: Receiving a list of questions or an information request from a health authority such as FDA, EMA, or PMDA can be a stressful and business-critical moment. How you respond determines whether your product moves forward to approval or faces further delays.
Our experienced team provides rapid, scientifically rigorous responses to health authority questions related to Drug Substance CMC sections — interpreting agency concerns accurately, drafting clear and compliant responses, and coord